Daniel M. Cimbora

机构：Amgen (United States) · ORCID：0000-0001-9835-1527

发表论文 67 篇 · 总被引 3994 次 · h-index 26

代表论文

• Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial (2019 · The Lancet · 被引 742)
• Inebilizumab for Treatment of IgG4-Related Disease (2024 · New England Journal of Medicine · 被引 144)
• B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets (2018 · Therapeutic Advances in Neurological Disorders · 被引 138)
• Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1 (2011 · Molecular Cancer Therapeutics · 被引 97)
• Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial (2021 · Multiple Sclerosis Journal · 被引 83)
• Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study (2016 · Arthritis Research & Therapy · 被引 82)